The Wits HIV Research Group (WHRG) is a well-organized, highly effective Clinical Trial Unit (CTU) with an international reputation built on the successful conduct of NIH sponsored multi-centre trails, as well as its work with other international research groups. The WHRG consists of five Clinical Research Sites (CRSs) supported by a coordinating centre. This group has the capacity to undertake research in 5 high priority areas of HIV clinical trial research. The priority areas include Optimization of Clinical Management of HIV;Drug Development and Translational Research;HIV Prevention;Prevention of Mother to Child Transmission of HIV;HIV Vaccine Research and Development;and Microbicide Development. The CTU will link with five leadership networks (ACTG, IMPAACT, Microbicide Network, HVTN and PTN), maximizing scientific and recruitment opportunities by effectively integrating prevention, vaccine and therapeutic clinical trials in children, adolescents and adults. The unit will build on an established track record of the University of the Witwatersrand ACTU (Site#11101), PACTG (Site#8051), HPTN (Site#001-7) and a track record of international collaboration for microbicide research. In addition to our excellent record of research, this CTU contains four sites with letters confirming their status as selected sites for collaboration on four networks. The WHRG has a talented and skilled group of senior investigators with international reputations supported by enthusiastic research teams who are committed to HIV prevention in resource poor settings and the identification and management of acute HIV infections. The research team of the CTU has demonstrated an ability to work collaboratively with each other in all facets of the five networks and on PEPFAR initiatives. It is our aim to create a synergistic, pluri-potential CTU that is able to implement world-class research. In so doing, we also aim to achieve financial and operational efficiencies through centralizing and consolidating critical clinical research functions such as staff training, protocol implementation, regulatory compliance, IRB submission, pharmacy importation and data and quality management. The WHRG has close collaboration and support from the local, provincial and national Departments of Health, as well as from its own institutions. ADMINISTRATIVE COMPONENT:

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project with Complex Structure Cooperative Agreement (UM1)
Project #
4UM1AI069463-07
Application #
8415783
Study Section
Special Emphasis Panel (ZAI1-BLG-A (M1))
Program Officer
Germuga, Donna E
Project Start
2007-03-15
Project End
2013-12-09
Budget Start
2013-02-01
Budget End
2013-12-09
Support Year
7
Fiscal Year
2013
Total Cost
$3,619,097
Indirect Cost
$347,174
Name
Wits Health Consortium (Pty), Ltd
Department
Type
DUNS #
639391218
City
Johannesburg
State
Country
South Africa
Zip Code
Nachman, Sharon; Zheng, Nan; Acosta, Edward P et al. (2014) Pharmacokinetics, safety, and 48-week efficacy of oral raltegravir in HIV-1-infected children aged 2 through 18 years. Clin Infect Dis 58:413-22
Grinsztejn, Beatriz; Hosseinipour, Mina C; Ribaudo, Heather J et al. (2014) Effects of early versus delayed initiation of antiretroviral treatment on clinical outcomes of HIV-1 infection: results from the phase 3 HPTN 052 randomised controlled trial. Lancet Infect Dis 14:281-90
Kojic, Erna Milunka; Kang, Minhee; Cespedes, Michelle S et al. (2014) Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women. Clin Infect Dis 59:127-35
Westreich, Daniel (2014) From exposures to population interventions: pregnancy and response to HIV therapy. Am J Epidemiol 179:797-806
Lindsey, Jane C; Hughes, Michael D; Violari, Avy et al. (2014) Predictors of virologic and clinical response to nevirapine versus lopinavir/ritonavir-based antiretroviral therapy in young children with and without prior nevirapine exposure for the prevention of mother-to-child HIV transmission. Pediatr Infect Dis J 33:846-54
Touzard Romo, F; Smeaton, L M; Campbell, T B et al. (2014) Renal and metabolic toxicities following initiation of HIV-1 treatment regimen in a diverse, multinational setting: a focused safety analysis of ACTG PEARLS (A5175). HIV Clin Trials 15:246-60
Safren, Steven A; Biello, Katie B; Smeaton, Laura et al. (2014) Psychosocial predictors of non-adherence and treatment failure in a large scale multi-national trial of antiretroviral therapy for HIV: data from the ACTG A5175/PEARLS trial. PLoS One 9:e104178
Safren, Steven A; Hendriksen, Ellen S; Smeaton, Laura et al. (2012) Quality of life among individuals with HIV starting antiretroviral therapy in diverse resource-limited areas of the world. AIDS Behav 16:266-77
Hanrahan, Colleen F; Westreich, Daniel; Van Rie, Annelies (2012) Verification bias in a diagnostic accuracy study of symptom screening for tuberculosis in HIV-infected pregnant women. Clin Infect Dis 54:1377-8; author reply 1378-9
Kuritzkes, Daniel R; Hakim, James G; Sanne, Ian (2012) Least among equals. Clin Infect Dis 54:876-7